TissueLabs provides a platform for 3D bioprinting that includes bioprinters, bioinks, and hydrogels to facilitate the creation of lab-grown tissues and organs. This technology addresses the need for reliable and reproducible models in tissue engineering and regenerative medicine, enhancing research capabilities and accelerating drug discovery.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Creating functional 3D tissues and organs in the lab requires specialized equipment and materials, often hindering research and development in tissue engineering and regenerative medicine. Reproducibility and reliability of lab-grown tissues remain a significant challenge.
Solution
TissueLabs offers an integrated bioprinting platform that provides researchers with the tools necessary to create tissues and organs in vitro. The platform includes a range of 3D bioprinters designed for various tissue engineering applications, MatriXpec™ hydrogels optimized for cell compatibility and structural support, and TissueCoat™ ECM surface coatings. By providing a comprehensive suite of products, TissueLabs aims to streamline the tissue engineering workflow, improve the reliability of tissue models, and accelerate advancements in regenerative medicine and drug discovery.
Target Audience
The primary target audience includes researchers in tissue engineering, regenerative medicine, and pharmaceutical companies involved in drug discovery and development.
Features
- TissueStart™ 3D Bioprinter for entry-level bioprinting applications
- TissueRay™ 3D Bioprinter for advanced bioprinting research
- MatriXpec™ Hydrogels for creating a supportive 3D environment for cells
- TissueCoat™ ECM Surface Coating to enhance cell attachment and function